福元医药(601089.SH)：左甲状腺素钠片获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received a drug registration certificate from the National Medical Products Administration for Levothyroxine Sodium Tablets (100μg), allowing the production of this medication [1] Group 1: Product Approval - The Levothyroxine Sodium Tablets were developed by Merck and were first approved for sale in France in June 1980 [1] - The drug was approved for domestic sale in China in July 1997 by the National Medical Products Administration [1] Group 2: Indications - Levothyroxine Sodium Tablets are indicated for the treatment of non-toxic goiter (with normal thyroid function) [1] - The medication is used to prevent the recurrence of goiter after thyroidectomy [1] - It serves as a replacement therapy for hypothyroidism [1] - The drug is also an adjunct treatment for hyperthyroidism when using antithyroid medications [1] - It is indicated for suppression therapy after thyroid cancer surgery [1] - The tablets are used in thyroid suppression tests [1]